Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Weifa
Weifa
Activities:
Manufacturing
Ingredients
Research & Development
X
LinkedIn
Trending Articles
Why smaller CDMOs should enhance their operational efficiency now: a CPHI expert guide
CPHI experts advise smaller CDMO's to invest in supply chain resilience, friend shoring and AI to keep up with the predicted uptick in funding for 2025
CPI collaborates with industry leaders to expedite drug manufacturing via digitisation
Digitising manufacturing technologies could allow enhanced ability to scale production, reduce costs and expedite the process
Adare expands global handling & packaging capabilities
The company will have enhanced compaction, milling, bin blending and tablet compression capabilities in Philadelphia, Ohio and Milan
Janssen to adopt Johnson & Johnson brand as the company celebrates 100 years of UK operation
The company's pharmaceutical and medical technology segments will combine under the Johnson & Johnson brand name in the UK
Making the most of each cell: single-use perfusion in biopharma processing
GEA kytero perfusion disk stack separators are pioneering the time- and cost-efficient harvesting of pharmaceutical proteins from cells and facilitating continuous processing,...
Upcoming event
ASGCT Annual Meeting 2024
7-11 May, 2024 | Meeting | Portland, OR
See all
Related Content
Finance
Weifa proposes separation of consumer health and B2B businesses
B2B business will become Vistin Pharma producing APIs and acting as a CMO for Weifa and other pharma companies
Research & Development
Clavis Pharma appoints Interim Chairman and Acting CEO
CFO Gunnar Manum will be Acting CEO until long-term solution is found
Regulatory
Anticancer agent – elacytarabine
Cytarabine can cross the blood–brain barrier and is useful in the treatment of CNS lymphomas, but the response is variable and resistance commonly develops
Research & Development
Clavis Pharma appoints chief business officer
Nicholas Adams takes the role at Norwegian firm
Regulatory
Leukaemia treatment gains fast track designation
Clavis Pharma’s elacytarabine currently in Phase III trial
Subscribe now